Compare Bristol-Myers Squibb Co (BMY) vs Oklo Inc (OKLO) Price & Performance

Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.

BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.

OKLO trades at $45.13, up 1.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $77.07. The company reported its first revenue of $1.2 million in Q2 2026 but posted a wider net loss of $0.28 per share, missing estimates. Key milestones include the Groves reactor achieving criticality, though cash burn remains high with operating cash flow negative $117 million in 2026.

The outlook balances significant growth potential in nuclear energy against substantial execution risks. Analyst sentiment is strongly bullish (77% buy ratings), but investors face risks from persistent losses, high spending, and project delays. The stock's trajectory hinges on successful commercialization of its Aurora reactors by the targeted 2028 startup.